Need professional-grade analysis? Visit stockanalysis.com
$1.12B
N/A
59
N/A
Price Chart
Risk-Adjusted Performance
Nykode Therapeutics ASA (NYKD) Price Performance
Nykode Therapeutics ASA (NYKD) trades on Oslo Stock Exchange in NOK. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at NOK3.43, up 9.41% from the previous close.
Over the past year, NYKD has traded between a low of NOK1.47 and a high of NOK3.88. The stock has gained 113.4% over this period. It is currently 11.7% below its 52-week high.
Nykode Therapeutics ASA has a market capitalization of $1.12B.
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Compare Nykode Therapeutics ASA
Side-by-side comparison against top Healthcare peers.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- Oslo Stock Exchange
- Currency
- NOK
- Country
- Norway
Financial Metrics
- Revenue (TTM)
- $453,000
- EBITDA
- $-27,856,000
- Profit Margin
- N/A
- EPS (TTM)
- -0.37
- Book Value
- 2.66
Technical Indicators
- 52 Week High
- NOK 4.10
- 52 Week Low
- NOK 1.44
- 50 Day MA
- NOK 3.26
- 200 Day MA
- NOK 2.39
- Beta
- 0.89
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 2483.34
- Price/Book
- 1.19
- Enterprise Value
- $487.11M